DocSun Biomedical Limited (“DocSun“) a leading medical research firm, today announced the completion of technology transfer to Future Now Biotech LLC (“Future Now”), a rapid growing biotech company. The transfer includes a wide range of proprietary technologies and intellectual property, including cutting-edge medical research and innovative medical devices.
“We are thrilled to be transferring our tech and IPs to Future Now,” said Mike Chen, CEO of DocSun Biomedical. “Our two companies share a common goal of improving healthcare and advancing medical technology, and this transfer will allow us to continue our mission on a larger scale.”
The transfer of technology and IP will enhance Future Now’s ability to bring innovative medical solutions to market faster, providing patients with the latest in cutting-edge medical technology. The company is committed to use DocSun technology to help advance medical research and improve patient outcomes.
“The acquisition of DocSun’s technologies and IPs is a significant step forward for Future Now,” said Gary Kiss, CEO of Future Now. “We look forward to leveraging these resources to help drive our growth and continue our mission of advancing medical technology for the betterment of human health.”
